Viome, GSK to develop cancer, autoimmune disease therapies

By The Science Advisory Board staff writers

Viome Life Sciences has expanded its partnership with GlaxoSmithKline (GSK) to develop potential therapies for cancer and autoimmune diseases.

Through the collaboration, Viome and GSK will examine the connection between the gut microbiome and the onset of specific chronic disorders. The companies will explore therapies using targets based on Viome's discovery platform, which analyzes host and microbial interaction at the onset and progression of diseases.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking